S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1379-1388

  Kaur, Jatinder ^a   Matta, Ajay ^a   Kak, Ipshita ^a   Srivastava, Gunjan ^a   Assi, Jasmeet ^a   Leong, Iona ^a,b   Witterick, Ian ^a,b   Colgan, Terence J ^a   Macmillan, Christina ^a   Siu, K W Michael ^c   Walfish, Paul G ^a,b   Ralhan, Ranju ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YORK UNIVERSITY   (Canada)

Author keywords

14 3 3 ; 14 3 3 ; biomarker; dysplasia; hnRNPK; immunohistochemistry; oral cancer; progression; PTMA; S100A7; transformation

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; PROTEIN P16; PROTHYMOSIN ALPHA; PSORIASIN;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; EARLY DIAGNOSIS; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOUTH SQUAMOUS CELL CARCINOMA; ORAL BIOPSY; ORAL DYSPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

EID: 84891834011     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28473     Document Type: Article

References (50)

1. Hunter KD, Parkinson EK, Harrison PR,. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
2. Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008; 37: 127-33.
3. Ho MW, Risk JM, Woolgar JA, et al. The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral Oncol 2012; 48: 969-76.
4. Mehanna HM, Rattay T, Smith J, et al. Treatment and follow-up of oral dysplasia-a systematic review and meta-analysis. Head Neck 2009; 31: 1600-9.
5. Warnakulasuriya S, Kovacevic T, Madden P, et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med 2011; 40: 677-83.
6. Nankivell P, Mehanna H,. Oral dysplasia: biomarkers, treatment, and follow-up. Curr Oncol Rep 2011; 13: 145-52.
7. Brennan M, Migliorati CA, Lockhart PB, et al. Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: S19.e1-S19.e12.
8. Rosin MP, Poh CF, Guillard M, et al. Visualization and other emerging technologies as change makers for oral cancer prevention. Ann N Y Acad Sci 2007; 1098: 167-83.
9. Pitiyage G, Tilakaratne WM, Tavassoli M, et al. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 2009; 38: 737-52.
10. Smith J, Rattay T, McConkey C, et al. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 2009; 45: 647-53.
11. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6: 357-62.
12. Zhang L, Poh CF, Williams M, et al. Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) 2012; 5: 1081-9.
13. Jayaprakash V, Reid M, Hatton E, et al. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010. Oral Oncol 2011; 47: 1048-54.
14. Angiero F, Gatta LB, Seramondi R, et al. Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res 2010; 30: 3435-40.
15. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008; 7: 1162-73.
16. Ralhan R, Desouza LV, Matta A, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009; 8: 300-9.
17. Matta A, DeSouza LV, Shukla NK, et al. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 2008; 7: 2078-87.
18. Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009; 125: 1398-406.
19. Tripathi SC, Matta A, Kaur J, et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One 2010; 5: e11939.
20. Tripathi SC, Matta A, Kaur J, et al. Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer. PLoS One 2011; 6: e19213.
21. Emberley ED, Murphy LC, Watson PH., S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004; 82: 508-15.
22. Moubayed N, Weichenthal M, Harder J, et al. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 2007; 133: 253-61.
23. Nasser MW, Qamri Z, Deol YS, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012; 72: 604-15.
24. Tsai YS, Jou YC, Lee GF, et al. Aberrant prothymosin-alpha expression in human bladder cancer. Urology 2009; 73: 188-92.
25. Wu CS, Chang KP, Chen LC, et al. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma. Oral Oncol 2012; 48: 516-22.
26. Freeman AK, Morrison DK., 14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. Semin Cell Dev Biol 2011; 22: 681-7.
27. Ye L, Sun PH, Martin TA, et al. Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells. Urol Oncol 2012.
28. McLachlin CM, Kandel RA, Colgan TJ, et al. Prevalence of human papillomavirus in sinonasal papillomas: a study using polymerase chain reaction and in situ hybridization. Mod Pathol 1992; 5: 406-9.
29. Fregonesi PA, Teresa DB, Duarte RA, et al. p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2003; 51: 1291-7.
30. Nemes JA, Deli L, Nemes Z, et al. Expression of p16 (INK4A), p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 344-52.
31. Cunningham LL, Jr, Pagano GM, Li M, et al. Overexpression of p16INK4 is a reliable marker of human papillomavirus-induced oral high-grade squamous dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 77-81.
32. König F, Krekeler G, Hönig JF, et al. Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas-a tissue microarray study. Anticancer Res 2007; 27: 283-8.
33. Geißler C, Tahtali A, Diensthuber M, et al. The role of p16 expression as a predictive marker in HPV-positive oral SCCHN-a retrospective single-center study. Anticancer Res 2013; 33: 913-16.
34. Tahtali A, Hey C, Geissler C, et al. HPV status and overall survival of patients with oropharyngeal squamous cell carcinoma-a retrospective study of a German Head and Neck Cancer Center. Anticancer Res 2013; 33: 3481-5.
35. Nichols AC, Dhaliwal SS, Palma DA, et al. Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013; 42: 9.
36. Woo SB, Cashman EC, Lerman MA,. Human papillomavirus-associated oral intraepithelial neoplasia. Mod Pathol 2013.
37. Banerjee AG, Bhattacharyya I, Vishwanatha JK,. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol Cancer Ther 2005; 4: 865-75.
38. Winter J, Pantelis A, Reich R, et al. Risk estimation for a malignant transformation of oral lesions by S100A7 and Doc-1gene expression. Cancer Invest 2011; 29: 478-84.
39. Zhou G, Xie TX, Zhao M, et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 2008; 27: 3527-38.
40. Kesting MR, Sudhoff H, Hasler RJ, et al. Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features. Oral Oncol 2009; 45: 731-6.
41. Suzuki F, Oridate N, Homma A, et al. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep 2005; 14: 1493-8.
42. Tsai ST, Jin YT, Tsai WC, et al. S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol 2005; 41: 349-57.
43. Morgan MR, Jazayeri M, Ramsay AG, et al. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. Oncogene 2011; 30: 1422-35.
44. Emberley ED, Niu Y, Curtis L, et al. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 2005; 65: 5696-702.
45. Emberley ED, Gietz RD, Campbell JD, et al. RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer 2002; 2: 28.
46. Ruse M, Broome AM, Eckert RL., S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes. J Invest Dermatol 2003; 121: 132-41.
47. Leõn R, Murray JI, Cragg G, et al. Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways. Biochemistry 2009; 48: 10591-600.
48. West NR, Watson PH., S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 2010; 29: 2083-92.
49. Emberley ED, Niu Y, Njue C, et al. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res 2003; 9: 2627-31.
50. Hwang SJ, Shroyer KR,. Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012; 2012: 507286.